

UNITED STATES PATENT AND TRADEMARK OFFICE

---

**BEFORE THE PATENT TRIAL AND APPEAL BOARD**

SLAYBACK PHARMA LLC

Petitioner

v.

EYE THERAPIES, LLC

Patent Owner

Patent No. 8,293,742

Filing Date: July 27, 2009

Issue Date: October 23, 2012

Title

PREFERENTIAL VASOCONSTRICTION COMPOSITIONS  
AND METHODS OF USE

---

Case No. IPR2022-00142

---

**PETITION FOR *INTER PARTES* REVIEW**

Filed November 4, 2021

**TABLE OF CONTENTS**

	<b><u>Page</u></b>
TABLE OF AUTHORITIES .....	7
LISTING OF EXHIBITS.....	9
I. INTRODUCTION .....	12
A. Summary of Grounds .....	14
B. Chain of Priority -- Earliest Effective Filing Date.....	14
C. Person of Ordinary Skill in the Art (POSA) .....	15
D. Background Facts .....	15
1. Vasoconstrictor Eye Drops to Reduce Eye Redness Were Known.....	15
2. 2-Imidazoline Derivatives Were Known as Vasoconstrictors to Reduce Eye Redness.....	16
3. Brimonidine Was Known as Potent Vasoconstrictor With Favorable Properties for Reducing Eye Redness.....	17
4. Brimonidine Was Approved in 1996 for Eye Drops .....	19
5. Prior Art Disclosed Brimonidine Drops to Reduce Eye Redness from LASIK Surgery .....	21
6. Prior Art Discloses “Low Concentrations” of Brimonidine, The Alleged Basis of the Claimed Invention.....	22
7. Prior Art Disclosed Brimonidine Eye Drops With pH 6.3 to 6.5.....	23
II. U.S. PATENT 8,293,742.....	24
A. Summary of the “Present Invention” .....	24

B.	Background of the Invention.....	24
C.	“Brimonidine” Is Defined Broadly .....	25
D.	“Ocular Conditions” Are Listed Broadly .....	25
E.	The 0.02% and 0.03% Brimonidine of the Prior Art Fall Within Preferred Ranges of the ‘742 Patent.....	26
III.	CLAIM CONSTRUCTION .....	26
A.	Claim Construction Is Needed for “about 0.025%”.....	26
B.	“about 0.025%” Includes “0.03%”.....	27
C.	“Ocular condition” .....	31
IV.	CLAIMS 1-6 ARE UNPATENTABLE .....	32
A.	Ground 1: Claims 1-2 Anticipated by ‘553 Patent.....	32
1.	U.S. Patent 6,294,553 .....	32
2.	Claim 1: Anticipated by ‘553 Patent Example 1 .....	33
a.	[1.P] “[a] method for reducing eye redness”.....	33
b.	[1.1] “consisting essentially of administering brimonidine” .....	34
c.	[1.2] “to a patient having an ocular condition” .....	35
d.	[1.3] “wherein brimonidine is present at a concentration between about 0.001% weight by volume and about 0.05% weight by volume” .....	35
3.	Claim 2: Anticipated by the ‘553 Patent.....	36
a.	[2.1] “wherein brimonidine is present at a concentration between about 0.001% to about 0.025% weight by volume” .....	36

B.	Ground 2: Claims 1-2 Anticipated by Walters 1991.....	37
1.	Walters 1991 .....	37
2.	Claim 1: Anticipated by Walters 1991 .....	40
a.	[1.P] “A method for reducing eye redness”.....	40
b.	[1.1] “consisting essentially of administering brimonidine” .....	41
c.	[1.2] “to a patient having an ocular condition” .....	42
d.	[1.3] “wherein brimonidine is present at a concentration between about 0.001% weight by volume and about 0.05% weight by volume” .....	42
3.	Claim 2: Anticipated by Walters 1991 .....	43
a.	[2.1] “wherein brimonidine is present at a concentration between about 0.001% to about 0.025% weight by volume”.....	43
C.	Ground 3: Claims 1-6 Are Obvious .....	44
1.	Patents and Printed Publications Listed in Ground 3 .....	44
a.	‘553 Patent .....	44
b.	Norden 2002 .....	46
c.	‘442 Patent .....	48
d.	Alphagan® Label 1998.....	48
e.	Federal Register 1988 .....	49
2.	Claims 1-6 Are Obvious Claim By Claim Analysis.....	50
a.	Claim 3 is Obvious .....	50

i.	[3.P] “A method for reducing eye redness consisting essentially of” [3.1] “topically administering to a patient having an ocular condition a composition” .....	50
ii.	[3.2] “to a patient having an ocular condition” ....	51
iii.	[3.3] “a composition consisting essentially of brimonidine” .....	52
iv.	[3.4] “into ocular tissue” .....	54
v.	[3.5] wherein pH of said composition is between about 5.5 and about 6.5 .....	55
vi.	[3.6] “wherein said brimonidine concentration is between about 0.001% and about 0.025% weight by volume” .....	56
b.	Claim 1 Is Obvious .....	60
c.	Claim 2 Is Obvious .....	60
d.	Claim 4 Is Obvious .....	61
e.	Claims 5 and 6 Are Obvious.....	62
D.	A Proper Comparison to the Prior Art Would Be to the 0.02% Brimonidine in Walters 1991 or the 0.03% Brimonidine in Example 1 of the ‘553 Patent .....	63
E.	The ‘553 Patent, Norden 2002 and Walters 1991 Were Not Before the Examiner During Prosecution .....	64
V.	MANDATORY NOTICES .....	65
A.	Real Parties-In-Interest.....	65
B.	Related Matters.....	65
C.	Identification of Counsel and Service Information.....	66

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.